Are the recorded data of flash glucose monitoring systems influenced by radiological examinations?

Takatsu, Yasuo; Shiozaki, Toshiki; Miyati, Tosiaki; Asahara, Masaki; Tani, Yasuhiro

doi:10.1007/s12194-019-00505-x

Cited by 9 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the hospital, patients often are instructed to remove the CGM prior to these procedures, although some sites allow for the sensor to be covered with a lead shield [ 19 ]. However, several studies have shown that the Dexcom G6 sensor and the Freestyle Libre Pro are accurate when exposed to X-ray, CT, radiotherapy [ 52 – 54 ], and possibly MRI (in the case of the Freestyle Libre Pro) [ 55 ].…”

Section: Other Safety Considerations and Interferencementioning

confidence: 99%

CGM in the Hospital: Is It Ready for Prime Time?

2022

View full text Add to dashboard Cite

Purpose of Review The use of continuous glucose monitoring (CGM) in the hospital setting is growing with more patients using these devices at home and when admitted to the hospital, especially during the COVID-19 pandemic. Recent Findings Historically, most evidence for CGM use in the inpatient setting was limited to small studies utilizing outdated CGM technology and analyzing accuracy of sensor measurements. Previous studies have shown reduced sensor accuracy during extreme hypo- or hyperglycemia, rapid fluctuations of glucose, compression of the sensor itself, and in those who are critically ill. Studies that are more recent have shown CGM to have adequate accuracy and may be effective in reducing hypoglycemia in hospitalized patients; some studies have also showed improvement in time in target glycemic range. Furthermore, CGM may reduce nursing workload, cost of inpatient care, and use of personal protective equipment and face-to-face patient care especially for patients during the COVID-19 pandemic. Summary This review will describe the evidence for use of CGM in hospitalized critically ill or non-critically ill patients, address accuracy and safety considerations, and outline paths for future implementation.

show abstract

Section: Other Safety Considerations and Interferencementioning

confidence: 99%

CGM in the Hospital: Is It Ready for Prime Time?

2022

View full text Add to dashboard Cite

show abstract

“…Newer CGM systems, namely Freestyle Libre 2 and 3 (Abbott Diabetes Care), Dexcom G6 and G7 (Dexcom, Inc., San Diego, CA; G7 only approved in Europe), and Guardian Sensor 4 (only approved in Europe), are minimally invasive, with a small flexible cannula inserted into the subcutaneous tissue that is attached to the back of the upper arm or abdomen for 10-14 days. Eversense (Senseonics, Inc.) is an implantable sensor that requires sensor removal and reinsertion every 180 days; although there is the need for an invasive procedure, it is overall well tolerated (Table 1) (44)(45)(46)(47)(48)(49).…”

Section: Use Of Continuous Glucose Monitoring In Managing Glycemiamentioning

confidence: 99%

Continuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD

Galindo

Boer

Neumiller

et al. 2022

CJASN

View full text Add to dashboard Cite

Treatment of patients with diabetes and CKD includes optimizing glycemic control using lifestyle modifications and drugs that safely control glycemia and improve clinical kidney and cardiovascular disease outcomes. However, patients with advanced CKD, defined as eGFR <30 mL/min/1.73m2 or kidney disease treated with dialysis, have limitations to use of some preferred glucose-lowering medications, are often treated with insulin, and experience high rates of severe hypoglycemia. Moreover, HbA1c accuracy decreases as GFR deteriorates. Hence, there is a need for better glycemic monitoring tools. Continuous glucose monitoring (CGM) allows 24-hour glycemic monitoring to understand patterns and the impact of lifestyle and medications. Realtime CGM can be used to guide administration of insulin and non-insulin therapies. CGM can overcome the limitations of self-monitored capillary glucose testing and HbA1c and has been shown to prevent hypoglycemic excursions in some populations. More data are needed to understand whether similar benefits can be obtained for patients with diabetes and advanced CKD. This review provides an updated approach to management of glycemia in advanced CKD, focusing on the role of CGM in this high-risk population.

show abstract

“…62,63 Currently, the incorporation of glucose alarms in more-recent CGM systems may potentially improve patient safety by minimizing and predicting hyperglycemia and hypoglycemia. The main limitations of CGM may be the potentially reduced accuracy in this setting, due to changes in tissue hydration (ischemia, edema, dehydration), compression of the glucose sensor by decubitus, possible drug interference, and the withdrawal need to some imaging tests (ie, magnetic resonance imaging) 64 or when using of diathermic therapies.…”

Section: Defining Objectives Of Glycemic Control According To Patient...mentioning

confidence: 99%

Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes

Bellido

Aguilera

Cardona-Hernández

et al. 2022

J Diabetes Sci Technol

View full text Add to dashboard Cite

New metrics for assessing glycemic control beyond HbA1c have recently emerged due to the increasing use of continuous glucose monitoring (CGM) in diabetes clinical practice. Among them, time in range (TIR) has appeared as a simple and intuitive metric that correlates inversely with HbA1c and has also been newly linked to the risk of long-term diabetes complications. The International Consensus on Time in Range established a series of target glucose ranges (TIR, time below range and time above range) and recommendations for time spent within these ranges for different diabetes populations. These parameters should be evaluated together with the ambulatory glucose profile (AGP). Using standardized visual reporting may help people with diabetes and healthcare professionals in the evaluation of glucose control in frequent clinical situations. The objective of the present review is to provide practical insights to quick interpretation of patient-centered metrics based on flash glucose monitoring data, as well as showing some visual examples of common clinical situations and giving practical recommendations for their management.

show abstract

Are the recorded data of flash glucose monitoring systems influenced by radiological examinations?

Cited by 9 publications

References 13 publications

CGM in the Hospital: Is It Ready for Prime Time?

CGM in the Hospital: Is It Ready for Prime Time?

Continuous Glucose Monitoring to Optimize Management of Diabetes in Patients with Advanced CKD

Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes

Contact Info

Product

Resources

About